EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

St. John's wort extract with a high hyperforin content does not induce P‐glycoprotein activity at the human blood–brain barrier

Myriam El Biali, Michael Wölfl-Duchek, Matthias Jackwerth, Severin Mairinger, Maria Weber, Karsten Bamminger iD, Stefan Poschner, Ivo Rausch iD, Natalie Schindler, Irene Hernández Lozano, Walter Jäger, Lukas Nics und 5 weitere

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Myriam El Biali und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hypericum, Blood-Brain Barrier, Phloroglucinol, Plant Extracts. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Austrian Science Fund FWF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

St. John's wort (SJW) extract, a herbal medicine with antidepressant effects, is a potent inducer of intestinal and/or hepatic cytochrome P450 (CYP) enzymes and P‐glycoprotein (P‐gp), which can cause clinically relevant drug interactions. It is currently not known whether SJW can also induce P‐gp activity at the human blood–brain barrier (BBB), which may potentially lead to decreased brain exposure and efficacy of certain central nervous system (CNS)‐targeted P‐gp substrate drugs. In this study, we used a combination of positron emission tomography (PET) imaging and cocktail phenotyping to gain a comprehensive picture on the effect of SJW on central and peripheral P‐gp and CYP activities. Before and after treatment of healthy volunteers ( n = 10) with SJW extract with a high hyperforin content (3–6%) for 12–19 days (1800 mg/day), the activity of P‐gp at the BBB was assessed by means of PET imaging with the P‐gp substrate [ 11 C]metoclopramide and the activity of peripheral P‐gp and CYPs was assessed by administering a low‐dose phenotyping cocktail (caffeine, omeprazole, dextromethorphan, and midazolam or fexofenadine). SJW significantly increased peripheral P‐gp, CYP3A, and CYP2C19 activity. Conversely, no significant changes in the peripheral metabolism, brain distribution, and P‐gp‐mediated efflux of [ 11 C]metoclopramide across the BBB were observed following the treatment with SJW extract. Our data suggest that SJW does not lead to significant P‐gp induction at the human BBB despite its ability to induce peripheral P‐gp and CYPs. Simultaneous intake of SJW with CNS‐targeted P‐gp substrate drugs is not expected to lead to P‐gp‐mediated drug interactions at the BBB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypericumBlood-Brain BarrierPhloroglucinolPlant ExtractsPositron-Emission TomographyTerpenesHumansMaleAdultFemaleYoung AdultATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily BBridged Bicyclo CompoundsTerfenadineCytochrome P-450 Enzyme SystemHealthy Volunteers

Substanzen

hyperforinPhloroglucinolPlant ExtractsTerpenesATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily BfexofenadineABCB1 protein, humanBridged Bicyclo CompoundsTerfenadine

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
  • QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
  • Laboratoire d'Imagerie Biomédicale Multimodale (BIOMAPS), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay, France.

ORCID-Profile: Karsten Bamminger, Ivo Rausch, Oliver Langer

Förderung

  • Austrian Science Fund FWF

Zitieren

APA

El Biali, M., Wölfl-Duchek, M., Jackwerth, M., Mairinger, S., Weber, M., Bamminger, K., Poschner, S., Rausch, I., Schindler, N., Lozano, I. H., Jäger, W., Nics, L., Tournier, N., Hacker, M., Zeitlinger, M., Bauer, M., & Langer, O. (2024). St. John's wort extract with a high hyperforin content does not induce P‐glycoprotein activity at the human blood–brain barrier. Clinical and Translational Science. https://doi.org/10.1111/cts.13804

Vancouver

El Biali M, Wölfl-Duchek M, Jackwerth M, Mairinger S, Weber M, Bamminger K, et al. St. John's wort extract with a high hyperforin content does not induce P‐glycoprotein activity at the human blood–brain barrier. Clinical and Translational Science. 2024. doi:10.1111/cts.13804

BibTeX
@article{ElBiali2024,
  author = {El Biali, Myriam and Wölfl-Duchek, Michael and Jackwerth, Matthias and Mairinger, Severin and Weber, Maria and Bamminger, Karsten and Poschner, Stefan and Rausch, Ivo and Schindler, Natalie and Lozano, Irene Hernández and Jäger, Walter and Nics, Lukas and Tournier, Nicolas and Hacker, Marcus and Zeitlinger, Markus and Bauer, Martin and Langer, Oliver},
  title = {St. John's wort extract with a high hyperforin content does not induce P‐glycoprotein activity at the human blood–brain barrier},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13804}
}
Kostenlos starten →